Athale Uma H, Gibson Paul J, Bradley Nicole M, Malkin David M, Hitzler Johann
Division of Hematology/Oncology, Hamilton Health Sciences, McMaster Children's Hospital, Hamilton, Ontario, Canada.
Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
Pediatr Blood Cancer. 2016 Jun;63(6):973-82. doi: 10.1002/pbc.25939. Epub 2016 Feb 23.
Minimal residual disease (MRD) is an independent predictor of relapse risk in children with leukemia and is widely used for risk-adapted treatment. This article summarizes current evidence supporting the use of MRD, including clinical significance, current international clinical practice, impact statement, and recommended indications. The proposed MRD recommendations have been endorsed by the MRD Working Group of the Pediatric Oncology Group of Ontario and provide the foundation for a strategy that aims at equitable access to MRD evaluation for children with leukemia.
微小残留病（MRD）是白血病患儿复发风险的独立预测指标，广泛应用于风险适应性治疗。本文总结了支持使用MRD的现有证据，包括临床意义、当前国际临床实践、影响声明和推荐适应症。拟议的MRD建议已得到安大略省儿科肿瘤学组MRD工作组的认可，为旨在让白血病患儿公平获得MRD评估的策略奠定了基础。
